Skip to main navigation Skip to search Skip to main content

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

  • Dan P Zandberg
  • , Jacob B Allred
  • , Ari J Rosenberg
  • , John M Kaczmar
  • , Paul Swiecicki
  • , Ricklie A Julian
  • , Andrew S Poklepovic
  • , Jessica R Bauman
  • , Minh D Phan
  • , Nabil F Saba
  • , Edgardo Rivera
  • , Kendrith Rowland
  • , Diwakar Davar
  • , Julia Cordes
  • , Alan L Ho
  • , Miao Zhang
  • , Stephanie A Berg
  • , Pamela N Munster
  • , Gary K Schwartz
  • University of Pittsburgh
  • Alliance Statistics and Data Management Center
  • University of Chicago
  • Hollings Cancer Center
  • University of Michigan Rogel Cancer Center
  • University of Arizona Cancer Center
  • Virginia Commonwealth University Health System
  • Temple University Health Systems
  • University of Oklahoma Health Sciences Center
  • Winship Cancer Institute of Emory University
  • Nevada Cancer Specialists
  • Carle Cancer Center
  • Mayo Clinic
  • Memorial Sloan-Kettering Cancer Center
  • MD Anderson Cancer Center
  • Dana-Farber/Partners CancerCare
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • Case Western Reserve University

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma'. Together they form a unique fingerprint.
Sort by

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science